Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced a strategic collaboration with the Ollie Hinkle Heart Foundation (OHHF) to expand access to its AI-powered VMS+™ cardiac imaging platform for children and adults with congenital and childhood-onset heart disease. The partnership aims to leverage Ventripoint's technology alongside OHHF's Take Heart Collective Impact Model, which unites healthcare providers, innovators, researchers, families, and social partners including Jovie's Joy and Ella's Umbrella to accelerate innovation and improve outcomes.
Under the collaboration, OHHF will initially provide financial support to place two VMS+™ systems within its healthcare partner network, with further opportunities for education, advocacy, research, technology adoption, and community engagement. Ventripoint's VMS+™ platform uses artificial intelligence and advanced cardiac modeling to deliver accurate measurements of heart structure and function from a standard echocardiogram, enhancing clinical decision-making and patient monitoring across a wide range of heart conditions.
"Improving outcomes for people living with heart disease begins with access to accurate, timely, and affordable cardiac imaging," said Joe Hostetter, Director of the Congenital Heart Disease Program at Ventripoint Diagnostics. "Together, we have an opportunity to expand access to advanced imaging solutions that help clinicians make more informed decisions and improve care throughout a patient's journey."
The partnership is rooted in the lived experiences of families who understand the importance of better information and safer testing options. Katie Nesselbush, Founder of Jovie's Joy and Social Partner of OHHF, noted, "As a mother of a child living with dilated cardiomyopathy, I know firsthand the impossible decisions families can face. Technologies like Ventripoint give physicians more information to guide care while reducing barriers and risk for families." Mark Hinkle, Co-Founder of OHHF, added, "When our son Ollie passed away at just 13 months old, we learned how quickly a child's condition can change. We can honor them by ensuring more children have access to the technology, information, and treatment options they never had."
Ventripoint's VMS+ platform is designed to provide gold-standard volumetric cardiac measurements equivalent to MRI, offering a more accessible and efficient alternative. The collaboration underscores a commitment to ensuring that no parent faces impossible decisions when seeking answers about their child's heart. For more information, visit ventripoint.com and ohhf.org.
